(90 days)
WMT- TCP Bone Graft is indicated for bony voids or gaps that are not intrinsic to the stability of the bony structure. The WMT-TCP is intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. WMT- TCP Bone Graft Substitute can be combined with autogenous bone marrow aspirate and/or blood. The product resorbs and is replaced with bone during the healing process.
The WMT- TCP Bone Graft Substitute is provided sterile for single use only and should not be resterilized.
Apatight-TCP Bone Graft Substitute is a porous calcium phosphate resorbable bone graft substitute for the repair of bony defects. Apatight is an osteoconductive implant with a trabecular structure that resembles the multidirectional interconnected porosity of human cancellous bone. Apatight-TCP Bone Graft Substitute guides the three-dimensional regeneration of bone in the defect site. When placed in direct contact with viable host bone, new bone grows in apposition to the calcium phosphate surfaces of the implant. filling the pores with new bone. As Apatight-TCP Bone Graft Substitute resorbs. bone grows into the space it previously occupied.
This document is a 510(k) Summary of Safety and Effectiveness for a medical device called WMT-TCP Bone Graft Substitute, submitted by Wright Medical Technology, Inc. It aims to establish substantial equivalence to a previously cleared device. Therefore, it does not contain the type of study data and acceptance criteria you've requested for a device performance study involving accuracy metrics like sensitivity, specificity, or AUC, as it's not evaluating an AI/diagnostic device.
The information provided describes the device's intended use and demonstrates its substantial equivalence to a predicate device (APATIGHT™- TCP Bone Graft Substitute, K013966) based on material composition and design features.
Here's how to interpret the available information in the context of your request:
1. A table of acceptance criteria and the reported device performance
This document does not specify quantitative acceptance criteria for device performance in the way a diagnostic or AI device would, nor does it report performance metrics like sensitivity, specificity, or AUC. The "acceptance" in this context is the FDA's determination of substantial equivalence to an existing legally marketed device.
Therefore, for this submission, the implicit "acceptance criterion" is generally:
| Acceptance Criterion (Implicit for Substantial Equivalence) | Reported Device Performance |
|---|---|
| The device (WMT- TCP Bone Graft Substitute) is as safe and effective as a legally marketed predicate device (APATIGHT™- TCP Bone Graft Substitute, K013966), and does not raise different questions of safety and effectiveness. This is demonstrated through similar intended use, material composition, and design features. | Substantial Equivalence Achieved: The FDA has determined the WMT-TCP Bone Graft Substitute is substantially equivalent to the predicate device (K013966) for the stated indications for use. The document explicitly states: "The intended use, material composition, and design features of the WMT- TCP Bone Graft Substitute are substantially equivalent to the intended use, material composition, and design features of the previously submitted APATIGHT™- TCP Bone Graft Substitute (K013966)." Furthermore, it states: "The safety and effectiveness of the WMT- TCP Bone Graft Substitute with the expanded indication is adequately supported by the substantial equivalence information, materials data, and testing results provided within this Premarket Notification." |
The remaining points (2-9) are not applicable or cannot be answered with the provided submission as it is not a study reporting on diagnostic accuracy, AI performance, or clinical trial outcomes in the way your questions are framed.
Here's why:
- 2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective): Not applicable. There is no "test set" in the context of evaluating diagnostic performance from images or other data. The evaluation is based on a comparison of device characteristics to a predicate device.
- 3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): Not applicable. No ground truth establishment for a test set of diagnoses or classifications.
- 4. Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable. No test set requiring expert adjudication.
- 5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This is not an AI-assisted diagnostic device.
- 6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. This is not an algorithm.
- 7. The type of ground truth used (expert consensus, pathology, outcomes data, etc): Not applicable. The "ground truth" here is the established safety and effectiveness of the predicate device, which the new device is compared against.
- 8. The sample size for the training set: Not applicable. There is no "training set" for an algorithm.
- 9. How the ground truth for the training set was established: Not applicable. There is no training set.
In summary, this document is an FDA 510(k) clearance summary for a bone graft substitute, aiming for substantial equivalence to a predicate device. It does not involve a performance study with acceptance criteria related to diagnostic accuracy, nor does it concern an AI or image-based diagnostic device.
{0}------------------------------------------------
5 2002 NOV
Image /page/0/Picture/2 description: The image shows the logo for Wright Medical Technology, Inc. The logo features a stylized "W" made up of three black triangles on the left side. To the right of the "W" is the company name, "WRIGHT MEDICAL TECHNOLOGY, INC." The address "5677 AIRLINE ROAD ARLINGTON, TN 38002" and phone number "901-867-9971" are printed below the company name.
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CRF 807, this information serves as a Summary of Safety and Effectiveness for the WMT - TCP Bone Graft Substitute.
| Submitted By: | Wright Medical Technology, Inc. |
|---|---|
| Date: | August 6, 2002 |
| Contact Person: | Ehab M. EsmailManager, Regulatory Affairs |
| Proprietary Name: | WMT- TCP Bone Graft Substitute |
| Common Name: | Bone Graft Substitute |
| Classification Name and Reference: | Filler, Calcium Sulfate Preformed Pellets,Unclassified. |
| Device Product Code and Panel Code: | Orthopedics/87/ MQV |
DEVICE INFORMATION
A. INTENDED USE
WMT- TCP Bone Graft is indicated for bony voids or gaps that are not intrinsic to the stability of the bony structure. The WMT-TCP is intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. WMT- TCP Bone Graft Substitute can be combined with autogenous bone marrow aspirate and/or blood. The product resorbs and is replaced with bone during the healing process.
The WMT- TCP Bone Graft Substitute is provided sterile for single use only and should not be resterilized.
Image /page/0/Picture/11 description: The image shows a black and white drawing of a globe. The globe is tilted on its axis and is sitting on a stand. The continents are visible on the globe, and the oceans are dark. The drawing is simple and has a vintage look.
$p^{1/2}$
{1}------------------------------------------------
B. DEVICE DESCRIPTION
Apatight-TCP Bone Graft Substitute is a porous calcium phosphate resorbable bone graft substitute for the repair of bony defects. Apatight is an osteoconductive implant with a trabecular structure that resembles the multidirectional interconnected porosity of human cancellous bone. Apatight-TCP Bone Graft Substitute guides the three-dimensional regeneration of bone in the defect site. When placed in direct contact with viable host bone, new bone grows in apposition to the calcium phosphate surfaces of the implant. filling the pores with new bone. As Apatight-TCP Bone Graft Substitute resorbs. bone grows into the space it previously occupied.
C. SUBSTANTIAL EQUIVALENCE INFORMATION
The intended use, material composition, and design features of the WMT- TCP Bone Graft Substitute are substantially equivalent to the intended use, material composition. and design features of the previously submitted APATIGHT"- TCP Bone Graft Substitute (K013966).
The safety and effectiveness of the WMT- TCP Bone Graft Substitute with the expanded indication is adequately supported by the substantial equivalence information, materials data, and testing results provided within this Premarket Notification.
Image /page/1/Picture/6 description: The image shows a black and white drawing of a cell. The cell appears to be round with a dark area on the right side and a lighter area on the left side. There is a dark ring around the top of the cell. The bottom of the cell is cut off from the image.
Image /page/1/Picture/7 description: The image shows the logo for Wright Medical Technology, Inc. The logo consists of the word "WRIGHT" in a bold, sans-serif font, with a stylized triangular shape above it. Below the word "WRIGHT" are the words "MEDICAL TECHNOLOGY, INC." in a smaller, sans-serif font.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICE
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the words "HUMAN SERVICES - USA" around the perimeter. In the center of the logo is a stylized symbol that resembles a person with outstretched arms, with three curved lines above the person.
9200 Corporate Boulevard Rockville MD 20850
Mr. Ehab M. Esmail Manager, Regulatory Affairs Wright Medical Technology, Inc. 5677 Airline Road Arlington, Tennessee 38002
Re: K022629
Trade/Device Name: WMT-TCP Bone Graft Substitute Regulatory Class: Unclassified Product Code: MQV Dated: August 6, 2002 Received: August 7, 2002
Dear Mr. Esmail:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally predicate device results in a classification for your device and thus, permits your device to proceed to the market.
{3}------------------------------------------------
Page 2 - Mr. Ehab M. Esmail
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours.
Marianne C. Barrett
ど、Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for Wright Medical Technology. The logo consists of a stylized "W" on the left, followed by the words "WRIGHT MEDICAL TECHNOLOGY" stacked on top of each other on the right. The "W" is made up of three thick, black, angled lines, and the text is in a simple, sans-serif font.
A Wright Medical Group Company
WMT-TCP Bone Graft Substitute
INDICATIONS STATEMENT
WMT- TCP Bone Graft is indicated for bony voids or gaps that are not intrinsic to the stability of the bony structure. The WMT-TCP is intended to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. WMT - TCP Bone Graft Substitute can be combined with autogenous bone marrow aspirate and/or blood. The product resorbs and is replaced with bone during the healing process.
The WMT- TCP Bone Graft Substitute is provided sterile for single use only and should not be resterilized.
Miriam C. Provost
Division of General, Restorative and Neurological Devices
510(k) Number K122627
Image /page/4/Picture/9 description: The image shows the logo for Wright Medical Technology, Inc. The logo features a stylized "W" symbol above the word "WRIGHT" in a serif font. Below "WRIGHT" are the words "MEDICAL TECHNOLOGY, INC." in a smaller, sans-serif font.
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.